SC
DYN icon

Steven Cohen’s Dyne Therapeutics DYN Stock Holding History

Steven Cohen’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-329,345
Closed -$6.44M – 3944
2025
Q4 		$6.44M Sell
329,345
-1,388,462
-81% -$26.3M 0.01% 1654
2025
Q3 		$21.7M Buy
1,717,807
+1,594,523
+1,293% +$18.2M 0.04% 528
2025
Q2 		$1.17M Sell
123,284
-1,405,250
-92% -$15.5M ﹤0.01% 1497
2025
Q1 		$16M Buy
1,528,534
+603,853
+65% +$8.64M 0.04% 512
2024
Q4 		$21.8M Buy
924,681
+822,201
+802% +$24.3M 0.05% 420
2024
Q3 		$3.68M Sell
102,480
-255,038
-71% -$10.2M 0.01% 970
2024
Q2 		$12.6M Sell
357,518
-328,916
-48% -$9.56M 0.03% 535
2024
Q1 		$19.5M Buy
686,434
+297,234
+76% +$6.72M 0.05% 460
2023
Q4 		$5.18M Sell
389,200
-186,600
-32% -$1.82M 0.01% 906
2023
Q3 		$5.16M Buy
575,800
+147,271
+34% +$1.59M 0.02% 868
2023
Q2 		$4.82M Sell
428,529
-492,606
-53% -$5.81M 0.01% 828
2023
Q1 		$10.6M Sell
921,135
-466,533
-34% -$6.06M 0.03% 535
2022
Q4 		$16.1M Sell
1,387,668
-109,963
-7% -$1.27M 0.05% 396
2022
Q3 		$19M Buy
1,497,631
+131,231
+10% +$1.5M 0.08% 337
2022
Q2 		$9.39M Sell
1,366,400
-521,500
-28% -$3.59M 0.04% 523
2022
Q1 		$18.2M Buy
1,887,900
+633,100
+50% +$5.39M 0.07% 351
2021
Q4 		$14.9M Buy
1,254,800
+427,800
+52% +$6.01M 0.06% 405
2021
Q3 		$13.4M Buy
827,000
+146,100
+21% +$2.59M 0.06% 414
2021
Q2 		$14.3M Buy
680,900
+327,785
+93% +$6.16M 0.06% 366
2021
Q1 		$5.48M Buy
+353,115
New +$6.83M 0.03% 551
2020
Q4 		– Sell
-20,000
Closed -$404K – 959
2020
Q3 		$404K Buy
+20,000
New +$439K ﹤0.01% 833

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Steven Cohen's DYN Position: Q1 2026 in Review

Steven Cohen sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 329,345 shares — an estimated $6.44M sold.

Steven Cohen first reported a position in DYN in Q3 2020 and held it in 21 quarters. The position peaked at $21.8M in Q4 2024. 228 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Steven Cohen reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 329,345 Dyne Therapeutics shares in Q1 2026, an estimated $6.44M.
  • Steven Cohen first reported a position in Dyne Therapeutics in Q3 2020 and held it in 21 quarters.
  • Steven Cohen's Dyne Therapeutics position peaked at $21.8M in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.